

**List of insider information under Art. 7 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 regarding market abuse (Regulation on market abuse), 30.06.2017**

**Dated 6 January 2017**

**NOTIFICATION**

2017 starts with good news concerning the registration and further development of our product Tabex. The buyer of the share of Sopharma AD in Extab – Achieve – is undertaking a merger with another strong player in the development and registration of innovative medicines – Oncogenex, a publicly traded company on NASDAQ (<http://in.reuters.com/article/idINFWN1EVOQP>). The procedure is expected to be completed by mid 2017 subject to approval from the US FSC. Sopharma AD will own approximately 3.5% in the newly created company, which will aim at filing the IND for Tabex in 2017.

Apart from the work on Tabex, the new company is also active in the development of other medicines, including one to facilitate the process of treating certain types of cancer.

**Dated 9 January 2017**

**NOTIFICATION**

Sopharma AD hereby notifies that the revenues from sales for 2016 decrease with 5% compared to 2015, including 2% decrease in domestic sales mainly due to the overall market price erosion (for the same period the company has a 7% increase in sales in packages) and a 6% decrease in export sales.

“In the past few months we see some signs for economic and political stabilization in Russia, which give us certain security for the results of 2017. We are optimistic for the trend of recovery of the sales in the Ukraine. After the restructuring of our export activities our local teams work systematically for the increase of the results on a number of markets like Poland, Belarus, Latvia, etc. We are very proud with the successful registrations of new products which we are yet to develop. An excellent example is Tuspan – the coughing syrup, which will be available on a number of European markets even this year in case of successful and timely procedures. This year started with a long-awaited news concerning our project of registration of our product Tabex in the USA. In case a restructuring takes place between Achieve and Oncogenex (our remaining shares in the capital of Extab will be transformed in shares in Achieve in case of such restructuring) there will be two advantages for us: first, the new joint team of the two companies will have a much bigger chance of a successful registration of Tabex and second, “Sopharma” AD will become a shareholder in a public company traded on NASDAQ.”, says Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors, “Sopharma” AD.

**Dated 2 February 2017**

**NOTIFICATION**

Sopharma AD announces that on 31 January, 2017 in accordance with art. 262e and the following from the Commercial Code Medica AD and Sopharma AD signed a contract for transformation through merger of Medica AD in Sopharma AD and the respective consequences following that decision. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0.9486, meaning that one share of Medica AD will be exchanged for 0.9486 shares of Sopharma AD. The companies have hired the services of certified appraisers whose report is a necessary prerequisite for the filing of the documents for transformation with the FSC. As of this moment the deputy Chairman "Investment Supervision" has not issued an approval in accordance with art. 124 from the LPOS of the transformation contract, of the reports of the BoD according to art. 262k from the Commercial code and the report of the appraiser under art. 262o from the Commercial Code.

**Dated 3 February 2017**

**NOTIFICATION**

For the first month of this year, revenues from sales decreased by 4% compared to the same period of 2015, including 5% decrease of domestic sales and 4% decrease of export sales.

**Dated 13 February 2017**

**NOTIFICATION**

Sopharma AD (the "Company") notifies that on 13 February 2017 the Contract for merger, as well as reports of the management bodies of the companies involved in the transformation of the company under art. 262i of the CA and the report of the examiner under art. 262m of the CA for transformation through merger between Sopharma AD, Sofia, UIC 831902088 and Medica AD, Kazanluk, UIC 000000993 were filed with the FSC for approval pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA). As a result of the merger, all assets of Medica AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Medica AD shall be terminated without liquidation.

As a result of the merger, all shareholders of the transferring company Medica AD, with the exception of the receiving company Sopharma AD, which is also a shareholder of the transferring company, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, app. 1 of the CA shall receive 0.9486 treasury shares of the capital of Sopharma AD. All other conditions concerning the merger procedure are included in the Contract.

**Dated 27 February 2017**

**NOTIFICATION**

Sopharma AD announces that the Competition Council of The Republic of Moldova allows the acquisition of over 51% of RAP Pharma International SRL by Sopharma AD.

**Dated 7 March 2017**

**NOTIFICATION**

For the first two months of this year, revenues from sales increased by 8% compared to the same period of 2016, including 5% decrease of domestic sales and 16% increase of export sales.

“We are very pleased with the results on the Russian market from the beginning of this year and the trend is strengthening in February reaching 40% increase in export sales.

We are hopeful also with regards to the registration of our product Tabex in the USA. After the news about the merger of Achieve and OncoGenex the good news continue. You can read more about the cooperation of Achieve with NIH here: [www.oncogenex.com](http://www.oncogenex.com).

The preliminary consolidated report of Sopharma Group for 2016 shows that even though the period was relatively difficult on our foreign markets, we still managed to reach a satisfactory EBITDA of 70 million BGN and a net profit of a little bit more than 50 million BGN. Analysis of the main indicators shows improved profitability due to optimization of main expenses and in the light of a maximum market price of a bit over 3 BGN for the year P/E is 8.31 and ROE is 10.9% compared to 5.3% for 2015.”, says Mr. Ognian Donev, PhD, CEO and Chairman of the Board of directors of Sopharma AD.

**Dated 9 March 2017**

**NOTIFICATION**

Sopharma AD announces that Sopharma AD received a final prohibition from the Bulgarian Financial Supervision Commission (FSC) to extend a tender offering to the shareholders of Unipharm AD. Sopharma AD is preparing a new tender offering which reflects the comments of the FSC.

**Dated 21 March 2017**

**NOTIFICATION**

Sopharma AD (the “Company”) notifies that on 20 March 2017 Sopharma AD, Sofia, UIC 831902088 and Medica AD, Sofia, UIC 000000993 signed an annex to the Contract for transformation through merger reflecting the comments by the FSC. All documents will be filed with the FSC for approval pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA) after an independent certified evaluator prepares a report.

As a result of the merger, all shareholders of the transferring company Medica AD, with the exception of the receiving company Sopharma AD, which is also a shareholder of the transferring company, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, app. 1 of the CA shall receive 0.8831 treasury shares of the capital of Sopharma AD. All other conditions concerning the merger procedure are included in the Contract.

**Dated 4 April 2017**

#### **NOTIFICATION**

For the first quarter of this year, revenues from sales increased by 12% compared to the same period of 2016, including 4% decrease of domestic sales and 24% increase of export sales.

"Sales on the Russian market in March reassert the uptrend since the beginning of the year and are a real indicator of improving the economic situation. At present, our forecast are that export sales will grow also over the next few months.", said Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors of "Sopharma" AD.

**Dated 6 April 2017**

#### **NOTIFICATION**

Sopharma AD (the "Company") hereby notifies that on 5 April 2017 Sopharma AD received a decision from the Commission for Protection of Competition that the acquisition of shares of the capital of Doverie Obedinen Holding AD is not subject to preliminary notification under art. 24, para 2 from the Law on Competition at this stage.

Sopharma AD will undertake the respective actions once it reaches the thresholds requiring a tender offering to the remaining shareholders of Doverie Obedinen Holding AD.

**Dated 18 April 2017**

#### **NOTIFICATION**

Sopharma AD notifies that after receiving a permission from the Moldova Competition Commission, Sopharma AD acquired 51% of the Moldova pharmaceutical distributor RAP Pharma International.

RAP PHARMA INTERNATIONAL (RAP) was established in 2004 and in 2014 started its activities in the pharmaceutical sector after receiving a license for pharmaceutical wholesaling and distribution. Currently the company owns 10 pharmacies and is the most intensively developing company in the Republic of Moldova. The revenues of the company for 2016 increased with almost 40% to 3 million EUR. The company has 79 employees and is one of the 7 distributors in Moldova owning a pharmacies network. The retail market in Moldova for 2016 according to Pharmexpert is about 100 million EUR (a precise statistics is not available). Currently the company is a distributor of the products of Sopharma AD, Medica AD, Momina krepost AD, STADA, GRINDEX - Baltics,

POLPHARMA, LEKPHARM - Belarus, FARMA PRIM - Moldova, FLUMED FARM - Moldova, BALKAN PHARMACEUTICALS - Moldova etc.. Since 2016 RAP Pharma is added in the list of companies supplying medicinal products to the State Hospitals in the Republic of Moldova through a centralized tender.

**Dated 26 April 2017**

## **NOTIFICATION**

Sopharma AD (the "Company") notifies that on 25 April 2017 the Financial Supervision Commission approved the Contract for transformation through merger and the additional annex to it, signed on 31 January 2017 between Sopharma AD, hereinafter referred to as "Acquirer" and Medica AD, hereinafter referred to as "Acquiree" in accordance with the requirements of art. 262d and following of the Commercial Act (CA). As a result the assets of Medica AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Medica AD will be terminated without liquidation. The Financial Supervision Commission also approved the reports of the management of the two companies, prepared in accordance with the regulations of art.262i of the CA and the reports of the appointed examiners of the participants in the transformation under art. 262M of the CA from 13 October 2014.

As a result of the merger, all shareholders of the Acquiree Medica AD, with the exception of the Acquirer Sopharma AD, which is also a shareholder of the Acquiree, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, art. 1 of the CA shall receive 0.8813 shares of the capital of Sopharma AD.

**Dated 3 May 2017**

## **NOTIFICATION**

Dear Shareholders,

The invitation for the Annual General Meeting of shareholders of Sopharma AD convened for 2 June, 2017 published in x3news, investor.bg and the website of the company [www.sopharmagroup.bg](http://www.sopharmagroup.bg) contains a technical mistake concerning the second date for the AGM, which is announced in case of lack of quorum on 2 June 2017:

In the first paragraph of the invitation the listed second date is 16 July 2017 and in the last paragraph the listed second date is 16 June 2017.

**We would hereby like to advise all shareholders that the correct second date under the conditions of art. 227, para 3 of the Commercial code for the Annual General Meeting of shareholders of Sopharma AD is 16 June 2017.**

**Dated 3 May 2017**

**NOTIFICATION**

For the first four months of this year, revenues from sales increased by 12% compared to the same period of 2016, including 1% increase of domestic sales and 18% increase of export sales.

**Dated 5 May 2017**

**NOTIFICATION**

Sopharma AD notifies that regarding listing of additional issues on the agenda of the Annual General Meeting of Shareholders of Sopharma AD, scheduled for 02.06.2017, we present an updated invitation. Materials related to the new issues are published together with the other materials for the meeting on 02.06.2017.

**Dated 9 May 2017**

**NOTIFICATION**

Sopharma AD notifies that pursuant to Art. 115, para 7, proposal 1 of the Public Offering of Securities Act, on 09.05.2017 additional issues to the agenda of the AGM of Medica AD were published in the Commercial Register under the terms of Art. 223a of the Commercial Code in connection with Art. 118, para 2, item 4 of POSA by SOPHARMA AD as a shareholder holding more than three months more than 5% of the voting shares in MEDICA AD. With this registration, the new issues are included in the agenda of the company's General Meeting scheduled for 02.06.2017.

We would like to inform you that the materials for the additional issues were published by Medica AD in the Commercial Register with an application dated 27.04.2017 and a registration dated 04.05.2017 and are the following:

Contract for transformation by merger of Medica AD into Sopharma AD and appendices thereto;

Annex 1 to the Contract for transformation by merger of Medica AD into Sopharma AD;

Report of the Management Board;

Report of the independent examiner;

**Dated 2 June 2017**

**NOTIFICATION**

Sopharma AD hereby notifies all shareholders of the Company about the decision of the AGM of Sopharma AD that took place on June 2th, 2017 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:

AGM approves the proposal by the Board of Directors for the distribution of dividend at the amount of 0.10 BGN /ten stotinki/ per share with dividend right.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the AGM on which the Annual Financial Report was approved and the decision for dividend was taken.

After the exact amount of the dividend has been determined, based on a list of shareholders, provided. In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary – through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country. Payment of dividend will commence within three months from the date of the AGM, on which the payment of dividend was approved.

**Dated 5 June 2017**

### **NOTIFICATION**

For the first five months of this year, revenues from sales increased by 15% compared to the same period of 2016, including 2% increase of domestic sales and 25% increase of export sales.

**Dated 07 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
01.06.2017	Buy	7 500	3.9810
01.06.2017	Buy	7 000	3.9810
01.06.2017	Buy	7 000	3.9800
01.06.2017	Buy	7 000	3.9800
01.06.2017	Buy	7 000	3.9800
01.06.2017	Buy	900	4.0300
01.06.2017	Buy	500	4.0480
01.06.2017	Buy	500	4.0480
01.06.2017	Buy	500	4.0490
01.06.2017	Buy	500	4.0490
01.06.2017	Buy	50	4.0410
01.06.2017	Buy	100	4.0410

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 8 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	80	4.3690
05.06.2017	Buy	500	4.3700
05.06.2017	Buy	2 420	4.3750
05.06.2017	Buy	850	4.3650
05.06.2017	Buy	850	4.3650
05.06.2017	Buy	850	4.3650
05.06.2017	Buy	450	4.3650
05.06.2017	Buy	3 000	4.3200
05.06.2017	Buy	3 000	4.3200
05.06.2017	Buy	150	4.3200
05.06.2017	Buy	850	4.3200
05.06.2017	Buy	200	4.3020
05.06.2017	Buy	300	4.3020
05.06.2017	Buy	3 000	4.3000
05.06.2017	Buy	1 000	4.2990
05.06.2017	Buy	2 000	4.3000
05.06.2017	Buy	1 750	4.3000
05.06.2017	Buy	650	4.3000
05.06.2017	Buy	1 000	4.3000
05.06.2017	Buy	500	4.3000
05.06.2017	Buy	500	4.3000
05.06.2017	Buy	50	4.3000
05.06.2017	Buy	1 000	4.2700
05.06.2017	Buy	2 000	4.2600
05.06.2017	Buy	254	4.2800
05.06.2017	Buy	137	4.2500
05.06.2017	Buy	200	4.2800
05.06.2017	Buy	4	4.2800
05.06.2017	Buy	50	4.2400
05.06.2017	Buy	54	4.2800
07.06.2017	Buy	1 000	4.3200
07.06.2017	Buy	201	4.3300

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 8 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

Sopharma" AD (the Company) announces that it was notified by „Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.06.2017	Buy	765	4.3000
05.06.2017	Buy	150	4.3000
05.06.2017	Buy	85	4.3000
05.06.2017	Buy	1 000	4.2810
05.06.2017	Buy	100	4.2700
07.06.2017	Buy	500	4.2950

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 8 June 2017**

### **NOTIFICATION**

Sopharma AD (the "Company") announces that on 7 June 2017 the Company received a notification for the acquisition of 503 000 shares, representing 0.37% of its capital, by "Donev investments holding" AD. After the transaction, the share of "Donev investments holding" AD in the capital of Sopharma AD reached 25.15%.

**Dated 9 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev, Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
--	------------------	-------------------------	-------------------------

05.06.2017	Buy	2000	4.269
06.06.2017	Buy	1 850	4.3
06.06.2017	Buy	150	4.3
06.06.2017	Buy	1 000	4.3

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 12 June 2017**

### NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction	Operation	Number of shares	Unit price (BGN)
08.06.2017	Buy	10	4.302

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 12 June 2017**

### NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction	Operation	Number of shares	Unit price (BGN)
09.06.2017	Buy	191	4.2760
09.06.2017	Buy	59	4.2760
09.06.2017	Buy	100	4.2900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 12 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
12.06.2017	Buy	4.3200	27
12.06.2017	Buy	4.3710	324
12.06.2017	Buy	4.3710	26
12.06.2017	Buy	4.4000	263

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 12 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

Sopharma" AD (the Company) announces that it was notified by „Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
08.06.2017	Buy	100	4.3000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 12 June 2017**

### **NOTIFICATION**

We would like to notify that Sopharma AD will initiate dividend payment of the voted on the AGM held on 2 June 2017 dividend of 0.10 BGN **on 21 August 2017**.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. 16 June 2017.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary – through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.

**Dated 14 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the “Company”) announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev*, *Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
12.06.2017	Buy	300	4.3720
13.06.2017	Buy	700	4.41

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 14 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the “Company”) announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev*, *Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
14.06.2017	Buy	100	4.37

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 15 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
13.06.2017	Buy	800	4.4100
13.06.2017	Buy	22	4.4100
13.06.2017	Buy	178	4.4100
13.06.2017	Buy	200	4.3900
13.06.2017	Buy	350	4.3900
13.06.2017	Buy	250	4.3900
14.06.2017	Buy	50	4.4000
14.06.2017	Buy	50	4.4000
14.06.2017	Buy	100	4.4000
14.06.2017	Buy	700	4.4000
14.06.2017	Buy	150	4.4000
14.06.2017	Buy	650	4.4000
14.06.2017	Buy	57	4.3800
14.06.2017	Buy	23	4.3700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 15 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

Sopharma" AD (the Company) announces that it was notified by „Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
12.06.2017	Buy	500	4.3600
13.06.2017	Buy	100	4.3750
13.06.2017	Buy	70	4.3900

13.06.2017	Buy	30	4.3900
14.06.2017	Buy	100	4.4000
14.06.2017	Buy	250	4.4000
14.06.2017	Buy	120	4.3810

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 15 June 2017**

### NOTIFICATION

We are pleased to announce that the next step in the process of merging Achieve Lifesciences and Oncogenex has been completed with the approval of the merger by the US SEC. OncoGenex will hold a special shareholder meeting on 1 August 2017 to vote the merger. Shortly after the newly formed entity will trade on NASDAQ stock exchange under the ticker symbol ACHV.

**Dated 16 June 2017**

### NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction	Operation	Number of shares	Unit price (BGN)
15.06.2017	Buy	100	4.2890
15.06.2017	Buy	200	4.3100

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 21 June 2017**

### NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
16.06.2017	Buy	100	4.3150
16.06.2017	Buy	60	4.3160
16.06.2017	Buy	40	4.3160
16.06.2017	Buy	200	4.3000
16.06.2017	Buy	120	4.3200
16.06.2017	Buy	60	4.2950
16.06.2017	Buy	200	4.3190
16.06.2017	Buy	100	4.3400
20.06.2017	Buy	500	4.4200
20.06.2017	Buy	100	4.4580

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 21 June 2017**

### **NOTIFICATION**

On the grounds of Art. 157 of POSA in connection with Art. 154 of the Public Offering of Securities Act and in connection with the expired deadline for acceptance of the tender offer submitted by Sopharma AD to the shareholders of Unipharm AD, we inform you about the results of the tender offering submitted by Sopharma AD for the purchase of the shares of the other shareholders of Unipharm AD.

Company, object of the offer: Unipharm AD, with management address Sofia 1797, Studentski grad, zh.k. Darvenitsa, Trayko Stanoev Str.

Tender offeror: Sopharma AD, with address: Sofia, Nadezhda district, 16, Iliensko shose Str.

Authorized investment intermediary: Elana Trading AD, with management address: Sofia, Sredets, 4, Kuzman Shapkarev Str., and license issued by FSC for carrying out activity as an investment intermediary on the basis of Decision No. 171 -IP / 08.03.2006

Price offered per share: BGN 4.35 (four leva thirty-five stotinki) Number of persons accepted the tender offer: 65 Shareholder with total number of shares: 1 125 021, representing 18.75% of the capital of Unipharm AD.

As a result of the tender offer and after the conclusion of the transactions with the shareholders that have accepted it, Sopharma AD will directly own 96.63% of the shares of Unipharm AD. Sopharma AD has the right, within three months from the closing date of the tender offer, to submit, after obtaining the approval of the FSC, an offer for the purchase of the shares of the remaining shareholders of Unipharm AD on the grounds of Art. 157a of POSA. In addition, according to the provisions of Art. 157b of the POSA, each shareholder is entitled to require from Sopharma AD to redeem his/her shares until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the proposal under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the tender offering of BGN 4.35 per share.

The results of the tender offering were published by the tender offeror in the newspapers "Capital Daily" and "Sega" as of 21.06.2017.

**Dated 26 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
22.06.2017	Buy	150	4.4330
22.06.2017	Buy	600	4.4000
22.06.2017	Buy	490	4.4000
22.06.2017	Buy	400	4.4000
22.06.2017	Buy	1 000	4.4000
22.06.2017	Buy	320	4.4000
22.06.2017	Buy	500	4.4000
22.06.2017	Buy	180	4.4000
22.06.2017	Buy	795	4.4000
22.06.2017	Buy	205	4.4000
22.06.2017	Buy	1 000	4.4000
22.06.2017	Buy	1 000	4.4000
23.06.2017	Buy	220	4.3990
23.06.2017	Buy	300	4.4000
23.06.2017	Buy	200	4.4100

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 28 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
26.6.2017 10:22	Buy	2 000	4.4000
26.6.2017 10:28	Buy	280	4.4000
26.6.2017 12:27	Buy	200	4.4000
26.6.2017 13:20	Buy	300	4.4000
26.6.2017 13:30	Buy	500	4.4000
26.6.2017 13:31	Buy	124	4.4000
26.6.2017 13:50	Buy	376	4.4000
26.6.2017 15:23	Buy	300	4.4400
26.6.2017 16:24	Buy	190	4.4400
26.6.2017 16:24	Buy	363	4.4470
26.6.2017 16:42	Buy	100	4.4470
26.6.2017 16:42	Buy	47	4.4470
26.6.2017 17:00	Buy	100	4.4480
26.6.2017 17:00	Buy	300	4.4480
27.6.2017 10:14	Buy	100	4.4500
27.6.2017 10:22	Buy	4 200	4.4500
27.6.2017 12:37	Buy	100	4.4920
27.6.2017 15:56	Buy	250	4.4650
27.6.2017 15:58	Buy	250	4.4890

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 30 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
28.6.2017 10:13	Buy	200	4.4650

28.6.2017 10:14	Buy	1 800	4.4650
28.6.2017 10:22	Buy	234	4.4990
28.6.2017 10:22	Buy	69	4.4990
28.6.2017 10:22	Buy	470	4.4990
28.6.2017 10:22	Buy	427	4.5000
28.6.2017 10:22	Buy	1 000	4.5000
28.6.2017 10:36	Buy	250	4.5290
28.6.2017 10:36	Buy	750	4.5300
28.6.2017 10:42	Buy	1 000	4.5400
28.6.2017 10:57	Buy	624	4.5500
28.6.2017 10:57	Buy	376	4.5500
29.6.2017 10:42	Buy	400	4.5500
29.6.2017 10:46	Buy	1 000	4.5310
30.6.2017 10:44	Buy	1 000	4.5000
30.6.2017 10:44	Buy	848	4.5000
30.6.2017 10:49	Buy	152	4.5000
30.6.2017 10:55	Buy	600	4.5000
30.6.2017 15:31	Buy	2 000	4.5000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.